Prednisone and MTX (ACT arm) | Certolizumab Pegol and MTX (CZP arm) | Abatacept and MTX (ABA arm) | Tocilizumab and MTX (TCZ arm) | P | |
---|---|---|---|---|---|
N | 38 | 42 | 39 | 33 | |
Age | 53.42 ± 16.74 | 51.93 ± 14.78 | 54.26 ± 16.19 | 53.39 ± 13.17 | 0.928a |
BMI | 26.11 ± 5.81 | 24.97 ± 4.79 | 26.18 ± 4.70 | 25.92 ± 5.25 | 0.690a |
Current smoker (%) | 15.79% | 16.67% | 10.26% | 24.24% | 0.464b |
ACPA positive (%) | 84.21% | 85.71% | 87.18% | 84.85% | 0.985b |
CDAI | |||||
Day 0 | 32.86 ± 14.51 | 30.53 ± 13.67 | 29.19 ± 19.00 | 27.68 ± 11.28 | 0.349a |
Week 12 | 7.51 ± 6.04 | 5.79 ± 4.77 | 6.02 ± 5.62 | 8.09 ± 8.98 | 0.335a |
Week 24 | 6.11 ± 5.69 | 4.25 ± 4.42 | 4.65 ± 5.43 | 6.23 ± 5.83 | 0.260a |
Remission-w24* (%) | 36.84% | 52.38% | 51.28% | 42.42% | 0.461b |
EULAR-Good response-w24 (%) | 78.95% | 88.1% | 84.62% | 69.7% | 0.312b |
CRP | |||||
Day 0 | 20 (9.75–40.25) | 13 (4.6–32) | 8.8 (4–30) | 8 (4.25-20) | 0.078c |
Week 24 | 2 (1-4.5) | 1 (0.5–2.08) | 2 (1-3.8) | 0.5 (0.4-1) | < 0.001c |
ESR | |||||
Day 0 | 35 (23.75–57.5) | 32 (19–58) | 28 (17–50) | 26 (16.5-39.75) | 0.273c |
Week 24 | 11 (5.75-21) | 9.5 (5.75–19.5) | 11 (7–23) | 2 (2–4) | < 0.001c |